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A B S T R A C T
In spite of numerous studies on vaccination for various species of Leishmania, research on the development of an
effective vaccine for L. tropica is very scarce. In silico epitope prediction is a new way to survey the best vaccine
candidates. Here, we predicted the best epitopes of six L. tropica antigens with vaccine capability against this
pathogen, using highly frequent HLA-I alleles. Based on the frequent HLA alleles, the protein sequences were
screened individually using four different MHC prediction applications, namely SYFPEITHI, ProPredI, BIMAS,
and IEDB. Several in silico assays including clustering, human similarity exclusion, epitope conservancy pre-
diction, investigating in experimental records, immunogenicity prediction, and prediction of population cov-
erage were performed to narrow the results and to find the best epitopes. The selected epitopes and their re-
stricted HLA-I alleles were docked and the final epitopes with the lowest binding energy (the highest binding
affinity) were chosen. Finally, the stability and the binding properties of the best epitope-HLA-I combinations
were analyzed using molecular dynamics simulation studies. We found ten potential peptides with strong
binding affinity to highly frequent HLA-I alleles that can be further evaluated as vaccine targets against L. tropica.
1. Introduction
Leishmaniases are a group of disease caused by several species of
genus Leishmania (Steverding, 2017). The most common clinical forms
of leishmaniases include visceral leishmaniasis1 (VL), cutaneous leish-
maniasis2 (CL), and mucocutaneous leishmaniasis3 (MCL) (Pace, 2014).
Despite a large number of leishmaniases cases and even the high
mortality rate of VL, there is no approved and available vaccine for any
of their clinical forms (Gillespie et al., 2016; World Health, 2010).
Given the side effects of drugs used for the treatment of leishmaniases
and the rising number of drug resistant strains (van Griensven et al.,
2010), the development of effective vaccines would be an essential
mean to control this set of tropical diseases.
L. tropica is a neglected Leishmania species which causes mainly CL
and rarely VL in many parts of the world, especially in countries located
in the Middle East and North Africa (Akhoundi et al., 2016; Rostamian
and Niknam, 2018; World Health, 2010). However, compared to other
CL- or VL-causing Leishmania species, studies on L. tropica are scarce
(Rostamian and Niknam, 2018), particularly with respect to its vaccine
development which has no report in the literature except our previous
work (Rostamian et al., 2018). Furthermore, L. tropica is biochemically,
serologically, and genetically heterogeneous (Rostamian and Niknam,
2018). The pathology of L. tropica is also different from other common
Leishmania species, such as L. major, in both humans and experimental
models (Bastien and Killick-Kendrick, 1992; Rostamian and Niknam,
2018). Given these issues, further studies on L. tropica are required.
Despite the role of CD8+ T cells in tissue damage, several studies
have clearly shown that their activation is required to control
Leishmania infections. The CD8+ T cells can not only take part in pri-
mary responses but they also can actively participate in resistance to
the reinfection (Basu et al., 2007; Belkaid et al., 2002; da Conceicao-
Silva et al., 1994; McElrath et al., 1988; Muller et al., 1994). Thus, it
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1 VL: visceral leishmaniasis.
2 CL: cutaneous leishmaniasis.
3 MCL: mucocutaneous leishmaniasis.
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